
Veterinary Oncology Development Strategy
Studies evaluating our lead veterinary immunotherapy candidate, MIE-201, in canine companion animals with multiple tumor types have consistently demonstrated immune activation, antitumor activity, increased survival and no signs of toxicity or adverse events. We plan to expand on these promising data by advancing MIE-201 into larger canine efficacy and safety field studies. Our veterinary management team is currently coordinating with regulatory authorities to develop an efficient and effective strategy to potentially advance MIE-201 toward conditional approval for canine cancers.
Veterinary Immuno-Oncology Program: Status and Plans
Candidate
Indication
Administration
Preclinical
Proof of Concept
Exploratory Studies
Efficacy
Field Studies
Safety
Field Studies
2023 - 2024 Plans
MIE-201
Solid Tumors
Intratumoral
Completed / Ongoing
Planned
Initiate Efficacy Field Studies;
Potential Safety Field Studies

Efficacy Field Study Objectives
-
Evaluate clinical dose
-
Identify immune activation relationship to dose level
-
Measure antitumor responses
-
Assess abscopal effects and durability of responses